These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18473713)

  • 1. Telmisartan as a metabolic sartan for targeting vascular failure.
    Inoue T; Node K
    Expert Opin Pharmacother; 2008 Jun; 9(8):1397-406. PubMed ID: 18473713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan: a different angiotensin II receptor blocker protecting a different population?
    Burnier M
    J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
    Tuck ML
    Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan, its potential therapeutic implications in cardiometabolic disorders.
    Yamagishi S; Nakamura K
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):79-83. PubMed ID: 18221077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function.
    Ono Y; Nakaya Y; Bando S; Soeki T; Ito S; Sata M
    Int Heart J; 2009 Jan; 50(1):73-83. PubMed ID: 19246848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
    Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
    Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
    Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
    Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
    Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
    Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
    Yamagishi S; Nakamura K; Matsui T
    Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are the pleiotropic effects of telmisartan clinically relevant?
    Rizos CV; Elisaf MS; Liberopoulos EN
    Curr Pharm Des; 2009; 15(24):2815-32. PubMed ID: 19689352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan: just an antihypertensive agent? A literature review.
    Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
    Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
    Fujimura A; Ushijima K; Ando H
    Hypertens Res; 2013 Feb; 36(2):183. PubMed ID: 23190691
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan.
    Inoue T; Taguchi I; Abe S; Toyoda S; Sakuma M; Node K
    J Clin Pharm Ther; 2011 Feb; 36(1):103-10. PubMed ID: 21198725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan promotes potential glucose homeostasis in stroke-resistant spontaneously hypertensive rats via peroxisome proliferator-activated receptor γ activation.
    Omote Y; Deguchi K; Kurata T; Yamashita T; Sato K; Hishikawa N; Abe K
    Curr Neurovasc Res; 2015; 12(1):91-7. PubMed ID: 25557372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.
    Deppe S; Böger RH; Weiss J; Benndorf RA
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):863-71. PubMed ID: 20509777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.
    Sasaki T; Noda Y; Yasuoka Y; Irino H; Abe H; Adachi H; Hattori S; Kitada H; Morisawa D; Miyatake K
    Hypertens Res; 2008 May; 31(5):921-9. PubMed ID: 18712048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Telmisartan in the treatment of hypertensive patients].
    Podzolkov VI; Tarzimanova AI
    Ter Arkh; 2017; 89(6):110-113. PubMed ID: 28745698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.